Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1 1

Status

Recruiting 3Completed 3Unknown 2Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Colorectal Neoplasms 199Breast Neoplasms 124Carcinoma, Non-Small-Cell Lung 121Glioblastoma 93Neoplasms 75Ovarian Neoplasms 72Rectal Neoplasms 61Brain Neoplasms 59Lung Neoplasms 56Colonic Neoplasms 55Neoplasm Metastasis 51Glioma 49Carcinoma, Renal Cell 46Fallopian Tube Neoplasms 38Gliosarcoma 35Pancreatic Neoplasms 31Carcinoma, Hepatocellular 27Melanoma 26Adenocarcinoma of Lung 24Astrocytoma 21Stomach Neoplasms 20Uterine Cervical Neoplasms 16Recurrence 16Prostatic Neoplasms 16Liver Neoplasms 16Adenocarcinoma, Bronchiolo-Alveolar 16Esophageal Neoplasms 15Adenocarcinoma 15Carcinoma, Ovarian Epithelial 14Kidney Neoplasms 13

Interventions

Gemcitabine 7Leucovorin 6Irinotecan 6Fluorouracil 6130-nm albumin-bound paclitaxel 6Albumin-Bound Paclitaxel 5napabucasin 4Capecitabine 4Paclitaxel 3Oxaliplatin 3Ocoxin 3Bevacizumab 3pembrolizumab 2entinostat 2Sorafenib 2Imatinib Mesylate 2Everolimus 2Cyclophosphamide 2Cisplatin 2Cetuximab 25,10-methylenetetrahydrofolic acid 2tislelizumab 1spartalizumab 1pralsetinib 1palbociclib 1irinotecan sucrosofate 1halofantrine 1guadecitabine 1fludarabine 1ficlatuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Digestive System Neoplasms × Bevacizumab × Clear all
NCT02753127 2023-11-15

CanStem303C

Sumitomo Pharma America, Inc.

Phase 3 Completed
1,253 enrolled 18 charts
Gastrointestinal

Colonic Diseases, Digestive System Diseases, Digestive System Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Intestinal Diseases, Intestinal Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Rectal Diseases, Colorectal Neoplasms

NCT04299880 2023-11-08

Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols

Sumitomo Pharma America, Inc.

Phase 1 Completed
7 enrolled
Gastrointestinal

Adenocarcinoma, Digestive System Diseases, Digestive System Neoplasms, Neoplasms, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Pancreatic Neoplasms

NCT01996306 2019-01-08

AXEPT

Epidemiological and Clinical Research Information Network

Phase 3 Completed
650 enrolled
Gastrointestinal

Digestive System Neoplasms, Gastrointestinal Neoplasms, Intestinal Neoplasms, Neoplasm Metastasis, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡